Physician profile
Olivia Mandic
NPI 1881370039
$1,290.00
in general payments reported to CMS, 2019-2025
25 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $354 · 2024: $811 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $150.01 | 2023-2024 | Reblozyl, Abecma |
| Janssen Biotech, INC. | $145.89 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $134.83 | 2023-2025 | |
| Springworks Therapeutics, INC. | $75.75 | 2025 | Ogsiveo |
| Glaxosmithkline, LLC. | $69.46 | 2024 | Ojjaara |
| Legend Biotech USA INC. | $60.53 | 2023-2024 | Carvykti |
| Incyte Corporation | $52.04 | 2023-2024 | Jakafi, Monjuvi |
| Alexion Pharmaceuticals, INC. | $51.88 | 2023-2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $51.79 | 2023-2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $51.27 | 2023-2024 | Iclusig |
| Jazz Pharmaceuticals INC. | $50.86 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $46.26 | 2024 | Darzalex, Tecvayli, Carvykti |
| Rigel Pharmaceuticals, INC. | $42.50 | 2023-2024 | Rezlidhia, Tavalisse |
| Acrotech Biopharma INC. | $33.91 | 2023-2024 | Beleodaq |
| Sobi, INC | $32.20 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $32.02 | 2023-2024 | Monjuvi |
| Seagen INC. | $31.72 | 2023 | Adcetris |
| Merck Sharp & Dohme LLC | $30.87 | 2024 | Prevymis |
| Novartis Pharmaceuticals Corporation | $28.34 | 2024 | |
| Biolinerx USA, INC. | $22.16 | 2024 | Aphexda |
| Lilly USA, LLC | $21.59 | 2024 | Jaypirca |
| Beigene USA, INC. | $21.53 | 2024 | Brukinsa |
| Genzyme Corporation | $19.83 | 2024 | |
| Sanofi-Aventis U.S. LLC | $16.52 | 2024 | |
| Melinta Therapeutics, LLC | $16.24 | 2023 | Rezzayo, Vabomere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Mandic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.